Table 4 Activity and efficacy analyses summary
From: Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
Best response | Outcome measures | |||
|---|---|---|---|---|
Previous treatment | PR | SD | PFS-6 | OS-12 |
All patients (n=41) | 10 (24.4%) | 11 (26.8%) | 6 (14.6%) | 5 (12.2%) |
PEFG (n=16) | 3 (18.7%) | 6 (37.5%) | 3 (18.8%) | 4 (25.0%) |
G (n=17) | 5 (29.4%) | 4 (23.5%) | 2 (11.8%) | 0 (0.0%) |
G → PEFG (=5) | 0 (0.0%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) |
F including | ||||
y (n=23) | 5 (21.7%) | 7 (30.4%) | 4 (17.4%) | 5 (21.7%) |
n (n=18) | 5 (27.8%) | 4 (22.2%) | 2 (11.8%) | 0 (0.0%) |
P including | ||||
y (n=22) | 3 (13.6%) | 7 (31.8%) | 3 (13.6%) | 4 (18.2%) |
n (n=19) | 7 (36.8%) | 4 (21.1%) | 3 (15.8%) | 1 (5.3%) |
n of lines | ||||
1 (n=35) | 9 (25.7%) | 10 (28.6%) | 6 (17.1%) | 5 (14.3%) |
>1 (n=6) | 1 (16.6%) | 1 (16.6%) | 0 (0.0%) | 0 (0.0%) |
